JP2019507721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507721A5 JP2019507721A5 JP2018528588A JP2018528588A JP2019507721A5 JP 2019507721 A5 JP2019507721 A5 JP 2019507721A5 JP 2018528588 A JP2018528588 A JP 2018528588A JP 2018528588 A JP2018528588 A JP 2018528588A JP 2019507721 A5 JP2019507721 A5 JP 2019507721A5
- Authority
- JP
- Japan
- Prior art keywords
- idh1
- mutation
- composition
- ras
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SDYPYTQPBOKFBU-QQXFXQEMSA-N CC/C=C(\C=C(/N)\N([C@@H](CC1)[NH+](N([C@H](C(NC(C2)CC2(F)F)=O)c2ccccc2Cl)C(CN=C2)=C=C2F)[O-])C1=O)/C#N Chemical compound CC/C=C(\C=C(/N)\N([C@@H](CC1)[NH+](N([C@H](C(NC(C2)CC2(F)F)=O)c2ccccc2Cl)C(CN=C2)=C=C2F)[O-])C1=O)/C#N SDYPYTQPBOKFBU-QQXFXQEMSA-N 0.000 description 1
- ZRRBGUOZDZSRFF-NBTWKBOSSA-N N#CC(C1)=CC=NC1N([C@@H](CC1)C(N([C@H](C(CCC(C2)CC2(F)F)=O)c2ccccc2Cl)c2cc(F)cnc2)=O)C1=O Chemical compound N#CC(C1)=CC=NC1N([C@@H](CC1)C(N([C@H](C(CCC(C2)CC2(F)F)=O)c2ccccc2Cl)c2cc(F)cnc2)=O)C1=O ZRRBGUOZDZSRFF-NBTWKBOSSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021089138A JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263580P | 2015-12-04 | 2015-12-04 | |
| US62/263,580 | 2015-12-04 | ||
| US201662300721P | 2016-02-26 | 2016-02-26 | |
| US62/300,721 | 2016-02-26 | ||
| PCT/US2016/064832 WO2017096309A1 (en) | 2015-12-04 | 2016-12-02 | Methods of treatment of malignacies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021089138A Division JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507721A JP2019507721A (ja) | 2019-03-22 |
| JP2019507721A5 true JP2019507721A5 (https=) | 2020-01-16 |
| JP6892448B2 JP6892448B2 (ja) | 2021-06-23 |
Family
ID=57610403
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528735A Active JP6852073B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性病変を処置する方法 |
| JP2018528588A Expired - Fee Related JP6892448B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性腫瘍の処置の方法 |
| JP2021038684A Pending JP2021098740A (ja) | 2015-12-04 | 2021-03-10 | 悪性病変を処置する方法 |
| JP2021089138A Withdrawn JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528735A Active JP6852073B2 (ja) | 2015-12-04 | 2016-12-02 | 悪性病変を処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038684A Pending JP2021098740A (ja) | 2015-12-04 | 2021-03-10 | 悪性病変を処置する方法 |
| JP2021089138A Withdrawn JP2021121636A (ja) | 2015-12-04 | 2021-05-27 | 悪性腫瘍の処置の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200268726A1 (https=) |
| EP (2) | EP3383433A1 (https=) |
| JP (4) | JP6852073B2 (https=) |
| KR (2) | KR102924995B1 (https=) |
| CN (1) | CN108883184A (https=) |
| AU (2) | AU2016362425B2 (https=) |
| CA (2) | CA3007218A1 (https=) |
| ES (1) | ES2905915T3 (https=) |
| IL (4) | IL299563A (https=) |
| MA (1) | MA43374A (https=) |
| MX (2) | MX391229B (https=) |
| WO (2) | WO2017096150A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2011050210A1 (en) * | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| NZ723859A (en) | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| JP2017529382A (ja) | 2014-09-29 | 2017-10-05 | アギオス ファーマシューティカルス，インコーポレーテッド | 治療活性を有する化合物及びその使用方法 |
| JP7220986B6 (ja) | 2015-02-04 | 2024-02-08 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療効果のある化合物及びその使用方法 |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| FI3362065T3 (fi) | 2015-10-15 | 2024-06-19 | Servier Lab | Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi |
| KR20180063125A (ko) | 2015-10-15 | 2018-06-11 | 아지오스 파마슈티컬스 아이엔씨. | 악성종양을 치료하기 위한 복합 요법 |
| KR102699521B1 (ko) | 2015-10-15 | 2024-08-26 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| MX392941B (es) | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11013733B2 (en) * | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US20210196701A1 (en) | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| US20220017490A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| US20220017489A1 (en) | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2020113216A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| JP2023503842A (ja) | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| US20230084515A1 (en) * | 2020-02-19 | 2023-03-16 | Vanderbilt University | Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy |
| EP4185273A1 (en) * | 2020-07-24 | 2023-05-31 | Lonza Bend Inc. | Spray drying of supersaturated solutions of api with acetic acid |
| WO2024229332A1 (en) * | 2023-05-03 | 2024-11-07 | Memorial Sloan-Kettering Cancer Center | Anti-cancer treatments and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055107A1 (en) | 1997-06-06 | 1998-12-10 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| PE20142098A1 (es) | 2012-01-06 | 2015-01-08 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de uso |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| JP2015512630A (ja) * | 2012-03-12 | 2015-04-30 | メモリアル スローン−ケタリング キャンサー センター | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 |
| AU2014287122B9 (en) | 2013-07-11 | 2018-11-01 | Les Laboratoires Servier | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer |
| AU2014295938B2 (en) | 2013-08-02 | 2018-07-19 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| CA2842635A1 (en) * | 2014-01-20 | 2015-07-20 | University Health Network | Pre-cancerous cells and their identification in the prevention and treatment of cancer |
| WO2015127173A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015127172A1 (en) * | 2014-02-20 | 2015-08-27 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| MA39725B1 (fr) | 2014-03-14 | 2021-09-30 | Les Laboratoires Servier Sas | Compositions pharmaceutiques de composés thérapeutiquement actifs |
| NZ723859A (en) * | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| JP2017529382A (ja) | 2014-09-29 | 2017-10-05 | アギオス ファーマシューティカルス，インコーポレーテッド | 治療活性を有する化合物及びその使用方法 |
| JP7220986B6 (ja) | 2015-02-04 | 2024-02-08 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療効果のある化合物及びその使用方法 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2016
- 2016-12-02 ES ES16816809T patent/ES2905915T3/es active Active
- 2016-12-02 IL IL299563A patent/IL299563A/en unknown
- 2016-12-02 CA CA3007218A patent/CA3007218A1/en not_active Abandoned
- 2016-12-02 US US15/781,019 patent/US20200268726A1/en not_active Abandoned
- 2016-12-02 AU AU2016362425A patent/AU2016362425B2/en active Active
- 2016-12-02 MA MA043374A patent/MA43374A/fr unknown
- 2016-12-02 WO PCT/US2016/064600 patent/WO2017096150A1/en not_active Ceased
- 2016-12-02 US US15/368,439 patent/US10188656B2/en active Active
- 2016-12-02 WO PCT/US2016/064832 patent/WO2017096309A1/en not_active Ceased
- 2016-12-02 JP JP2018528735A patent/JP6852073B2/ja active Active
- 2016-12-02 KR KR1020187019185A patent/KR102924995B1/ko active Active
- 2016-12-02 CN CN201680080463.0A patent/CN108883184A/zh active Pending
- 2016-12-02 MX MX2018006745A patent/MX391229B/es unknown
- 2016-12-02 CA CA3007363A patent/CA3007363A1/en active Pending
- 2016-12-02 MX MX2018006831A patent/MX380596B/es unknown
- 2016-12-02 IL IL298663A patent/IL298663A/en unknown
- 2016-12-02 JP JP2018528588A patent/JP6892448B2/ja not_active Expired - Fee Related
- 2016-12-02 EP EP16816817.7A patent/EP3383433A1/en not_active Withdrawn
- 2016-12-02 KR KR1020187018928A patent/KR20180086255A/ko not_active Ceased
- 2016-12-02 AU AU2016363011A patent/AU2016363011B2/en not_active Ceased
- 2016-12-02 EP EP16816809.4A patent/EP3383400B1/en active Active
-
2018
- 2018-06-03 IL IL259783A patent/IL259783A/en unknown
- 2018-06-03 IL IL259787A patent/IL259787A/en unknown
-
2021
- 2021-03-10 JP JP2021038684A patent/JP2021098740A/ja active Pending
- 2021-05-12 US US17/318,606 patent/US20220000878A1/en not_active Abandoned
- 2021-05-27 JP JP2021089138A patent/JP2021121636A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507721A5 (https=) | ||
| JP2019502669A5 (https=) | ||
| JP2021098740A5 (https=) | ||
| JP2018535951A5 (https=) | ||
| JP2018536636A5 (https=) | ||
| JP2023530351A5 (https=) | ||
| JP2019533670A5 (https=) | ||
| JP2019532051A5 (https=) | ||
| JP2019513694A5 (https=) | ||
| Wilson et al. | Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma | |
| Sundar et al. | Predictive biomarkers of immune checkpoint inhibition in gastroesophageal cancers | |
| JP2020514311A5 (https=) | ||
| JP2014523516A5 (https=) | ||
| JP2018534286A5 (https=) | ||
| Wang et al. | Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers | |
| Oza et al. | Homologous recombination repair deficiency as a therapeutic target in sarcoma | |
| JP2018526376A5 (https=) | ||
| JP2017508805A5 (https=) | ||
| FI3362065T3 (fi) | Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi | |
| JP2018534288A5 (https=) | ||
| Wells Jr et al. | Update: the status of clinical trials with kinase inhibitors in thyroid cancer | |
| JP2016512831A5 (https=) | ||
| Long et al. | Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment | |
| Ettrich et al. | Regorafenib | |
| JP2019506392A5 (https=) |